JP6001650B2 - Cdc42抑制剤およびその応用 - Google Patents
Cdc42抑制剤およびその応用 Download PDFInfo
- Publication number
- JP6001650B2 JP6001650B2 JP2014511708A JP2014511708A JP6001650B2 JP 6001650 B2 JP6001650 B2 JP 6001650B2 JP 2014511708 A JP2014511708 A JP 2014511708A JP 2014511708 A JP2014511708 A JP 2014511708A JP 6001650 B2 JP6001650 B2 JP 6001650B2
- Authority
- JP
- Japan
- Prior art keywords
- cdc42
- zcl278
- compound
- bromo
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000011068 Cdc42 Human genes 0.000 title claims description 115
- 108050001278 Cdc42 Proteins 0.000 title claims description 115
- 239000003112 inhibitor Substances 0.000 title claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical group [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 claims description 5
- -1 step 3 Chemical compound 0.000 claims description 5
- VCDBRFZHSIYFRO-UHFFFAOYSA-N 2-(4-bromo-2-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Br)C=C1Cl VCDBRFZHSIYFRO-UHFFFAOYSA-N 0.000 claims description 4
- KQQRZZUQKPZRPM-UHFFFAOYSA-N 2-(4-bromo-2-chlorophenoxy)acetyl chloride Chemical compound ClC(=O)COC1=CC=C(Br)C=C1Cl KQQRZZUQKPZRPM-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- VIBJPUXLAKVICD-UHFFFAOYSA-N 4-bromo-2-chlorophenol Chemical compound OC1=CC=C(Br)C=C1Cl VIBJPUXLAKVICD-UHFFFAOYSA-N 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- ABTGINBBIGLLOF-UHFFFAOYSA-N ethyl 2-(4-bromo-2-chlorophenoxy)acetate Chemical compound CCOC(=O)COC1=CC=C(Br)C=C1Cl ABTGINBBIGLLOF-UHFFFAOYSA-N 0.000 claims description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 150000002540 isothiocyanates Chemical class 0.000 claims description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 claims 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- XKZDWYDHEBCGCG-UHFFFAOYSA-N 2-(4-bromo-2-chlorophenoxy)-n-[[4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl]carbamothioyl]acetamide Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(NC(=S)NC(=O)COC=3C(=CC(Br)=CC=3)Cl)=CC=2)=N1 XKZDWYDHEBCGCG-UHFFFAOYSA-N 0.000 description 81
- 210000004027 cell Anatomy 0.000 description 70
- DEFBCZWQLILOJF-UHFFFAOYSA-N NSC 23766 Chemical compound CCN(CC)CCCC(C)NC1=NC(C)=CC(NC=2C=C3C(N)=CC(C)=NC3=CC=2)=N1 DEFBCZWQLILOJF-UHFFFAOYSA-N 0.000 description 25
- 239000000556 agonist Substances 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 230000004913 activation Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000009087 cell motility Effects 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 101150058540 RAC1 gene Proteins 0.000 description 11
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 11
- 102000013515 cdc42 GTP-Binding Protein Human genes 0.000 description 11
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 11
- 230000001537 neural effect Effects 0.000 description 11
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 101150111584 RHOA gene Proteins 0.000 description 10
- 108010079515 intersectin 1 Proteins 0.000 description 10
- 210000000020 growth cone Anatomy 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000003855 cell nucleus Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 102000007469 Actins Human genes 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 102000016731 rac GTP-Binding Proteins Human genes 0.000 description 7
- 108010092883 rac GTP-Binding Proteins Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 5
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000004292 cytoskeleton Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 238000003125 immunofluorescent labeling Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000001392 Wiskott Aldrich Syndrome protein Human genes 0.000 description 4
- 108010093528 Wiskott Aldrich Syndrome protein Proteins 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 238000005094 computer simulation Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000003518 stress fiber Anatomy 0.000 description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 230000009400 cancer invasion Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000002288 golgi apparatus Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000003660 reticulum Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 206010048409 Brain malformation Diseases 0.000 description 2
- 102000001534 GDP dissociation inhibitor Human genes 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108010092964 Guanine Nucleotide Dissociation Inhibitors Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 208000012056 cerebral malformation Diseases 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DCGAZEUEQCRILY-UHFFFAOYSA-N (2-oxo-1,3,2lambda5-dioxaphosphetan-2-yl) dihydrogen phosphate Chemical compound OP(O)(=O)OP1(=O)OCO1 DCGAZEUEQCRILY-UHFFFAOYSA-N 0.000 description 1
- HAUHNCHOZRUXRI-UHFFFAOYSA-N 2-(4-bromo-3-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Br)C(Cl)=C1 HAUHNCHOZRUXRI-UHFFFAOYSA-N 0.000 description 1
- 102000004373 Actin-related protein 2 Human genes 0.000 description 1
- 108090000963 Actin-related protein 2 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150086838 CDC42 gene Proteins 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 101100121612 Dictyostelium discoideum rdiA gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101001040734 Homo sapiens Golgi phosphoprotein 3 Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- ZSSUKQHPALINBY-UHFFFAOYSA-N Secamine Natural products CCC1=CCCN(CCc2c3C(CCC(C(=O)OC)(c4[nH]c5ccccc5c4CCN6CCC=C(CC)C6)n3c7ccccc27)C(=O)OC)C1 ZSSUKQHPALINBY-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- QARVLSVVCXYDNA-IDEBNGHGSA-N bromobenzene Chemical group Br[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 QARVLSVVCXYDNA-IDEBNGHGSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000003520 dendritic spine Anatomy 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 1
- 229960002435 fasudil Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000003652 golgi cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- YREOGEATBXGQCH-UHFFFAOYSA-N n-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC=CC=2)=N1 YREOGEATBXGQCH-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000013152 negative regulation of cell migration Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 230000007511 neuronal proliferation Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- WOAYDXMBHOUEQZ-GJEPMKPZSA-N secramine Chemical compound C1=CC(OC)=CC=C1CS[C@H](C\C(C[C@H]1O2)=N\OCC=3C=CC=CC=3)[C@]31C[C@@H](CO)NCC1=CC(OCC4CC4)=C(Br)C2=C31 WOAYDXMBHOUEQZ-GJEPMKPZSA-N 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- 230000036448 vitalisation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
- C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
その名称は以下のとおりであり:
4−(3−(2−(4−Bromo−2−chlorophenoxy)acetyl)thioureido)−N−(4,6−dimethylpyrimidin−2−yl)benzenesulfonamide、即ち4−(3−(2−(4−ブロモ−2−クロロフェノキシ)アセチル)チオウレイド)−N−(4,6−ジメチルピリミジン−2−イル)ベンゼンスルホンアミドである。本明細書ではZCL278と略す。
前記化合物は心臓血管疾患の治療薬に調製される。
前記化合物は呼吸器疾患の治療薬に調製される。
前記化合物は神経系疾患の治療薬に調製される。
前記化合物はCdc42を抑制する機能により前記の作用を発揮する。
本発明のもう一つの目的は上記の式Ιに示された化合物を含むCdc42抑制剤を提供することである。
図1Aは、コンピュータシミュレーションによるCdc42分子中に結合したZCL278を示す。(実際に得られたカラーチャート:灰色表面(図の中の矢印1)がタンパク質を示し、緑の線(図の中の矢印2)がリガンドを示す。)図1BはZCL278とCdc42のアミノ酸残基との間の相互作用を示す図であり:ZCL278分子は緑の線(図の中の矢印3)で表され、Cdc42は灰色で描画され、Cdc42の残基は灰色の線(図の中の矢印4)で表され、2つの分子間の水素結合はオレンジの破線(図の中の矢印5)で表される。図1Cは、Cdc42−ZCL278複合体と、GMP−PCPタンパク質分子(タンパク質データベースID:2QRZ)の構造を重ねた図を示す:緑の線がZCL278分子を示し、灰色がCdc42の構造を示し、青い線がGMP−PCP構造を示す(GMP−PCPはGTP類似物、β,γ−メチレン二リン酸グアニルである)。
図2A−図2CはZCL278の活性特性を表示している。その中:図2Aは、ZCL278がCdc42によるマイクロスパイク形成を抑制することを示す。図2Bは、ZCL278が内生型Rac/Cdc42の活性化を抑制することを示す。図2Cは、ZCL278が刺激型Cdc42の活性化を抑制することを示す。
図3A−図3Cは、活性化Cdc42/リン酸化RhoAの免疫蛍光染色を示す。
図4は、ZCL278が、GM130タンパクが結合したゴルジ体を破壊することを示す。
図5A−図5Cは、ZCL278が、細胞の生存に影響を与えることなく、細胞の運動を抑制することを示す。
図6A−図6Cは、ZCL278がニューロンの枝分かれと成長円錐の運動を抑制することを示す。
反応式は以下のとおりである。:
Claims (7)
- 次の式Ιの構造を持つ化合物を含むことを特徴とする悪性腫瘍治療用薬物。
- 悪性腫瘍細胞の増殖と浸潤の予防治療に用いられることを特徴とする請求項1に記載の悪性腫瘍治療用薬物。
- 次の式Ιの構造を持つ化合物を含むことを特徴とする心臓血管疾患治療用薬物。
- 次の式Ιの構造を持つ化合物を含むことを特徴とする呼吸器疾患治療用薬物。
- 次の式Ιの構造を持つ化合物を含むことを特徴とする神経系疾患治療用薬物。
- 次の式Ιの構造を持つ化合物を含むことを特徴とするCdc42阻害剤。
- 4−ブロモ−2−クロロフェノールとエチルブロモアセテートとを、K 2 CO 3 の存在
下で反応させ、2−(4−ブロモ−2−クロロフェノキシ)酢酸とするステップ1、
ステップ1で得られた2−(4−ブロモ−2−クロロフェノキシ)酢酸エチルをアルカ
リ性条件下で加水分解し、2−(4−ブロモ−2−クロロフェノキシ)酢酸とするステッ
プ2、
ステップ2で得られた2−(4−ブロモ−2−クロロフェノキシ)酢酸を、N,N−ジ
メチルホルムアミドの触媒作用によって、塩化チオニルの中で還流反応を行い、2−(4
−ブロモ−2−クロロフェノキシ)アセチルクロリドとするステップ3、
ステップ3で得られた2−(4−ブロモ−2−クロロフェノキシ)アセチルクロリドと
チオシアン酸ナトリウムが、対応するイソチオシアネート中間体を形成した後、反応系に
4−アミノ−N−(4,6−ジメチル−2−ピリミジニル)ベンゼンスルホンアミドを投
入し、4−(3−(2−(4−ブロモ−2−クロロフェノキシ)アセチル)チオウレイド)−N−(4,6−ジメチルピリミジン−2−イル)ベンゼンスルホンアミドを作製するステップ4、
を含むことを特徴とする次の式Iの構造を持つ化合物の調製方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110135073.8 | 2011-05-23 | ||
CN201110135073 | 2011-05-23 | ||
PCT/CN2012/000708 WO2012159456A1 (zh) | 2011-05-23 | 2012-05-21 | 一种cdc42抑制剂及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014515357A JP2014515357A (ja) | 2014-06-30 |
JP6001650B2 true JP6001650B2 (ja) | 2016-10-05 |
Family
ID=47195390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014511708A Active JP6001650B2 (ja) | 2011-05-23 | 2012-05-21 | Cdc42抑制剤およびその応用 |
Country Status (6)
Country | Link |
---|---|
US (3) | US20140194451A1 (ja) |
EP (1) | EP2716292B1 (ja) |
JP (1) | JP6001650B2 (ja) |
KR (1) | KR20140028078A (ja) |
CN (1) | CN102796050B (ja) |
WO (1) | WO2012159456A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2716292B1 (en) | 2011-05-23 | 2017-09-06 | ONCO Biomedical Technology (Suzhou) Co., Ltd | Cdc42 inhibitor and uses thereof |
US11439608B2 (en) | 2017-09-25 | 2022-09-13 | Qun Lu | Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
EP3999053A4 (en) * | 2019-07-17 | 2023-07-19 | Children's Hospital Medical Center | METHOD OF TREATING NEOPLASTIC DISEASES USING A SPECIFIC CDC42 INHIBITOR |
CA3151110A1 (en) * | 2019-08-16 | 2021-02-25 | Children's Hospital Medical Center | Methods of treating a subject with a cdc42-specific inhibitor |
CN115068480B (zh) * | 2022-08-09 | 2023-10-20 | 郑州大学第一附属医院 | 细胞分裂周期蛋白42小分子抑制剂在制备治疗慢性肾脏病药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
EP2467362A4 (en) * | 2009-08-17 | 2013-06-26 | Brigham & Womens Hospital | INHIBITORS OF PHOSPHATIDYLCHOLINE TRANSFER PROTEIN |
EP2521553A4 (en) * | 2010-01-06 | 2013-08-28 | Errico Joseph P | METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS |
EP2716292B1 (en) * | 2011-05-23 | 2017-09-06 | ONCO Biomedical Technology (Suzhou) Co., Ltd | Cdc42 inhibitor and uses thereof |
-
2012
- 2012-05-21 EP EP12789644.7A patent/EP2716292B1/en active Active
- 2012-05-21 CN CN201210158276.3A patent/CN102796050B/zh active Active
- 2012-05-21 JP JP2014511708A patent/JP6001650B2/ja active Active
- 2012-05-21 WO PCT/CN2012/000708 patent/WO2012159456A1/zh active Application Filing
- 2012-05-21 KR KR1020137034199A patent/KR20140028078A/ko not_active Application Discontinuation
-
2013
- 2013-11-22 US US14/087,662 patent/US20140194451A1/en not_active Abandoned
-
2015
- 2015-07-23 US US14/807,386 patent/US9725417B2/en active Active
-
2017
- 2017-08-08 US US15/671,388 patent/US20170334863A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN102796050A (zh) | 2012-11-28 |
KR20140028078A (ko) | 2014-03-07 |
US9725417B2 (en) | 2017-08-08 |
US20140194451A1 (en) | 2014-07-10 |
EP2716292A4 (en) | 2014-12-03 |
JP2014515357A (ja) | 2014-06-30 |
US20150329496A1 (en) | 2015-11-19 |
CN102796050B (zh) | 2014-07-23 |
WO2012159456A1 (zh) | 2012-11-29 |
EP2716292B1 (en) | 2017-09-06 |
EP2716292A1 (en) | 2014-04-09 |
US20170334863A1 (en) | 2017-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6001650B2 (ja) | Cdc42抑制剤およびその応用 | |
JP2018528246A (ja) | Tead転写因子自己パルミトイル化阻害剤 | |
JP2009521471A (ja) | カルシウムチャネルアンタゴニスト | |
US9682919B2 (en) | Small molecule inhibitors of Dusp6 and uses therefor | |
RO120542B1 (ro) | Derivaţi de beta-aminotetralină, ca liganzi pentru receptorul y5 al neuropeptidei y, utilizaţi în tratamentul obezităţii şi al altor tulburări | |
TW200902010A (en) | Anthranilamide inhibitors of aurora kinase | |
KR20130121818A (ko) | Stat 단백질의 저해제로서의 치환된 2-히드록시-4-(2-(페닐설폰아미도)아세트아미도)벤조산 유사체 | |
JP2009521461A (ja) | カルシウムチャネルアンタゴニスト | |
WO2011051375A1 (en) | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them | |
KR100792587B1 (ko) | 유레아 화합물을 유효성분으로 함유하는 포유동물세포의노화방지제 | |
CN106977474A (zh) | 一种取代2‑氰基‑3‑苯基呋喃‑丙烯酰胺衍生物及其制备方法和用途 | |
US9278919B1 (en) | Synthesis of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide | |
Zhao et al. | Cell active and functionally-relevant small-molecule agonists of calcitonin receptor | |
Ha et al. | Angiotensin II modulates p130Cas of podocytes by the suppression of AMP-activated protein kinase | |
WO2024011657A1 (zh) | 细胞分裂调控重要着丝粒蛋白cenp-n靶向抑制剂cenpenlin及其应用 | |
US12084418B2 (en) | Small molecule inhibitors of G(alpha)i2 protein and uses thereof | |
JP2019085381A (ja) | アポトーシス誘導剤と癌治療剤 | |
KR20030020414A (ko) | Cdc25 포스파타제 억제제 | |
US10214502B2 (en) | Method of inhibiting apolipoprotein-E expression while increasing expression of at least one of LDL-receptor protein or AbcA1 protein comprising administering a small compound | |
WO2020246488A1 (ja) | NuMA1およびCKAP5を含む複合体を安定化する化合物 | |
CN108358855B (zh) | 一类含二苯甲胺的喹唑啉衍生物及其应用 | |
US9353093B2 (en) | Indole-1-carboxamides as kinase inhibitors | |
KR101793254B1 (ko) | 아크릴로니트릴 화합물 및 이를 포함하는 약학 조성물 | |
WO2011053090A2 (ko) | 신규한 2, 4-피리미딘 유도체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140715 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150402 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160802 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160901 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6001650 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |